149 related articles for article (PubMed ID: 9951688)
1. Establishment of a monoclonal antibody to human myeloma cell: relation to chemotherapy and extramedullar infiltration.
Kuribayashi N; Hata H; Matsuzaki H; Yoshida M; Sonoki T; Nagasaki A; Kimura T; Harada N; Takatsuki K
Med Oncol; 1998 Dec; 15(4):248-54. PubMed ID: 9951688
[TBL] [Abstract][Full Text] [Related]
2. Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake.
Harada N; Nagasaki A; Hata H; Matsuzaki H; Matsuno F; Mitsuya H
Acta Haematol; 2000; 103(3):144-51. PubMed ID: 10940652
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of a CD95 (Fas/Apo-1)-negative myeloma cell line.
Kuribayashi N; Hata H; Yoshida M; Sonoki T; Nagasaki A; Kimura T; Harada N; Matsuzaki H
Acta Haematol; 1999; 101(3):113-8. PubMed ID: 10352328
[TBL] [Abstract][Full Text] [Related]
4. c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB.
Greco C; D'Agnano I; Vitelli G; Vona R; Marino M; Mottolese M; Zuppi C; Capoluongo E; Ameglio F
Int J Immunopathol Pharmacol; 2006; 19(1):67-79. PubMed ID: 16569345
[TBL] [Abstract][Full Text] [Related]
5. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of 2-chlorodeoxyadenosine and melphalan myeloma cell lines.
Hjertner O; Börset M; Waage A
Leuk Res; 1996 Feb; 20(2):155-60. PubMed ID: 8628014
[TBL] [Abstract][Full Text] [Related]
7. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
8. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma.
Zheng Y; Yang J; Qian J; Qiu P; Hanabuchi S; Lu Y; Wang Z; Liu Z; Li H; He J; Lin P; Weber D; Davis RE; Kwak L; Cai Z; Yi Q
Leukemia; 2013 Mar; 27(3):702-10. PubMed ID: 22996336
[TBL] [Abstract][Full Text] [Related]
9. Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma.
Timm MM; Kimlinger TK; Haug JL; Kline MP; Greipp PR; Rajkumar SV; Kumar SK
Leukemia; 2006 Oct; 20(10):1863-9. PubMed ID: 16932343
[TBL] [Abstract][Full Text] [Related]
10. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
Spanswick VJ; Craddock C; Sekhar M; Mahendra P; Shankaranarayana P; Hughes RG; Hochhauser D; Hartley JA
Blood; 2002 Jul; 100(1):224-9. PubMed ID: 12070031
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.
Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M
Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262
[TBL] [Abstract][Full Text] [Related]
12. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
13. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma.
Boccadoro M; Palumbo A; Bringhen S; Merletti F; Ciccone G; Richiardi L; Rus C; Bertola A; Giaccone L; Omedè P; Musto P
Haematologica; 2002 Aug; 87(8):846-50. PubMed ID: 12161361
[TBL] [Abstract][Full Text] [Related]
14. Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.
Zheng Y; Cai Z; Wang S; Zhang X; Qian J; Hong S; Li H; Wang M; Yang J; Yi Q
Blood; 2009 Oct; 114(17):3625-8. PubMed ID: 19710503
[TBL] [Abstract][Full Text] [Related]
15. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
Ramachandran IR; Condamine T; Lin C; Herlihy SE; Garfall A; Vogl DT; Gabrilovich DI; Nefedova Y
Cancer Lett; 2016 Feb; 371(1):117-24. PubMed ID: 26639197
[TBL] [Abstract][Full Text] [Related]
16. Proteometabolomics of Melphalan Resistance in Multiple Myeloma.
Koomen DC; Guingab-Cagmat JD; Oliveira PS; Fang B; Liu M; Welsh EA; Meads MB; Nguyen T; Meke L; Eschrich SA; Shain KH; Garrett TJ; Koomen JM
Methods Mol Biol; 2019; 1996():273-296. PubMed ID: 31127562
[TBL] [Abstract][Full Text] [Related]
17. Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector.
Yang ZZ; Chen XH; Wang D
Clin Lymphoma Myeloma; 2007 Jan; 7(4):296-304. PubMed ID: 17324338
[TBL] [Abstract][Full Text] [Related]
18. Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.
Xiang Y; Remily-Wood ER; Oliveira V; Yarde D; He L; Cheng JQ; Mathews L; Boucher K; Cubitt C; Perez L; Gauthier TJ; Eschrich SA; Shain KH; Dalton WS; Hazlehurst L; Koomen JM
Mol Cell Proteomics; 2011 Nov; 10(11):M110.005520. PubMed ID: 21846842
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
20. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma.
Nimmanapalli R; Gerbino E; Dalton WS; Gandhi V; Alsina M
Br J Haematol; 2008 Aug; 142(4):551-61. PubMed ID: 18503584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
